Open-label, Multicenter, Dose-escalation/Expansion Phase Ib Study to Evaluate Safety, Pharmacokinetics, and Activity of BET Inhibitor RO6870810, Given as Mono- and Combination Therapy to Patients With Advanced Multiple Myeloma

Next Previous
Trial Profile

Open-label, Multicenter, Dose-escalation/Expansion Phase Ib Study to Evaluate Safety, Pharmacokinetics, and Activity of BET Inhibitor RO6870810, Given as Mono- and Combination Therapy to Patients With Advanced Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2018

At a glance

  • Drugs Daratumumab (Primary) ; RG 6146 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche

    • Most Recent Events

    • 11 Dec 2017 Planned End Date changed from 18 May 2019 to 15 Jan 2020.
    • 11 Dec 2017 Planned primary completion date changed from 18 May 2019 to 15 Jan 2020.
    • 09 Nov 2017 Planned End Date changed from 15 Jan 2020 to 18 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top